Divi’s Joins ₹3 Trillion Market Cap Club After 15% Post-Q2 Rally

Divi’s Earnings Momentum Lifts Its Market Standing

Strong custom synthesis growth and wider margins have pushed Divi’s Laboratories into a new market-cap tier, while raising expectations for its next growth phase.

A results-led rally brings a new milestone

Divi’s shares reached a record ₹11,818 in intraday trade, extending gains after the company reported its second-quarter results. The stock had risen for 12 consecutive trading sessions, gaining 32% over that stretch and advancing 105% from its 52-week low of ₹5,648. The rally lifted its market capitalisation above ₹3 trillion for the first time.

At 9:40 a.m., the company was valued at ₹3.09 trillion, with its shares up 5% at ₹11,656.75, while the Sensex was down 0.32%. Divi’s ranked 30th by market capitalisation and became the second-largest pharmaceutical company by that measure after Sun Pharmaceutical Industries, whose market capitalisation was ₹4.6 trillion. The contrast with the broader index underscores the strength of the company-specific earnings response, but does not by itself establish how long the share-price momentum will last.

Custom synthesis drives revenue and margin gains

Revenue rose 35% year on year to ₹3,676 crore. Custom Synthesis (CS), the largest contributor to the quarter’s growth, increased 44% to ₹2,200 crore. Nutraceuticals revenue grew 13% to ₹273 crore, while generics rose 4.3% to ₹1,050 crore. The company said healthy volume growth across segments supported the performance.

Adjusted profit after tax climbed 64% to ₹1,127 crore, while EBITDA increased 76.4% to ₹1,566 crore. EBITDA margin expanded by 989 basis points to 42.6%, and gross profit margin improved by 739 basis points to 67.9%. Higher CS contribution and improved gross margins were identified as key factors. The figures show that the quarter’s growth translated into stronger profitability, not just higher sales.

Validation projects offer a pipeline, not a guarantee

The quarter’s CS performance was supported by shipments of validation batches. ICICI Securities said three large dedicated projects were moving through validation, with one nearing commercialisation and the other two expected to reach that stage in coming quarters. It also pointed to three new projects, each involving estimated capital expenditure of ₹650–700 crore, that could be commercialised from the second half of FY27 or in FY28.

These developments could support further growth if projects progress into commercial production as expected. However, validation activity is not the same as recurring commercial revenue, making execution and timing central to the outlook. Divi’s is also investing in capacity across peptides, key starting materials and nutraceuticals, which may support expansion but means capital expenditure will remain elevated.

Analyst optimism meets pressure in generics

Jefferies described the results as significantly ahead of its estimates and highlighted growth across the company’s divisions. It maintained a Buy rating with a ₹12,550 target. Choice Institutional Equities raised its FY27 and FY28 earnings estimates by 15.6% and 23.4%, respectively, and revised its target price to ₹12,650 while retaining an Add rating. These are brokerage views, not assured outcomes.

The risk picture is not uniform across businesses. Management expects generics pricing pressure to persist for some more quarters, even as it guides for double-digit revenue growth with sustained margins. Investors will need to assess whether the momentum in custom synthesis and margin improvement can offset that pressure and justify the expectations embedded in the recent rally.

Key Highlights

• Divi’s market capitalisation crossed ₹3 trillion for the first time.
• Second-quarter revenue rose 35% to ₹3,676 crore; adjusted profit increased 64% to ₹1,127 crore.
• Custom Synthesis grew 44% to ₹2,200 crore and led the revenue expansion.
• EBITDA margin widened to 42.6%, helped by product mix and improved gross margins.
• Project commercialisation and elevated capital expenditure are important execution factors.
• Generics pricing pressure is expected to continue for several more quarters.

Investor Note: Divi’s results point to strong operating momentum, but investors may want to distinguish near-term validation-driven growth from sustained commercial revenue and weigh the company’s expansion plans against generics pricing pressure and the sharp share-price advance.